Operations Commence at Haridwar Formulation Unit II (FDF) for Oncology

Operations Commence at Haridwar Formulation Unit II (FDF) for Oncology

• Year: 2021
• February 17, 2021

The Haridwar Formulation Unit II, specializing in Finished Dosage Forms (FDF) for oncology, has officially begun operations. This new facility is set to enhance the production of critical oncology medications, reinforcing the company's commitment to providing high-quality pharmaceutical solutions for cancer treatment. The launch of Unit II is expected to significantly contribute to the availability of essential oncology products in the market, addressing the growing demand for effective therapies in the fight against cancer.